David T. Howton's Insider Trades & SAST Disclosures
David T. Howton's most recent trade in Solid Biosciences Inc was a trade of 14,687 Common Stock done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David T. Howton.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Solid Biosciences Inc | David Tyronne Howton | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 14,687 | 30,350 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | David Tyronne Howton | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 14,687 | 44,063 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | David Tyronne Howton | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 3.96 per share. | 13 Feb 2025 | 5,561 | 24,789 (0%) | 0% | 4.0 | 22,022 | Common Stock |
| Solid Biosciences Inc | David Tyronne Howton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 169,100 | 169,100 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Tyronne David Howton | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 13,051 | 26,103 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Howton David Tyronne | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 13,051 | 20,735 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Tyronne Howton David | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 5.60 per share. | 02 Dec 2024 | 5,072 | 15,663 (0%) | 0% | 5.6 | 28,396 | Common Stock |
| Solid Biosciences Inc | David Tyronne Howton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 117,500 | 117,500 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Howton Tyronne David | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 58,750 | 58,750 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Howton David Tyronne | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2023 | 13,051 | 39,154 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Howton Tyronne David | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2023 | 13,051 | 13,051 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Howton David Tyronne | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.78 per share. | 02 Dec 2023 | 5,367 | 7,684 (0%) | 0% | 2.8 | 14,920 | Common Stock |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.85 per share. | 22 Jun 2020 | 56,984 | 91,993 (0%) | 0% | 23.8 | 1,359,068 | Common Stock |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 56,984 | 0 | - | - | Stock option (right to buy) | |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 171.50 per share. | 22 Jun 2020 | 55,270 | 31,871 (0%) | 0% | 171.5 | 9,478,805 | Common Stock |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.03 per share. | 22 Jun 2020 | 45,000 | 136,993 (0%) | 0% | 29.0 | 1,306,350 | Common Stock |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 45,000 | 7,708 | - | - | Stock option (right to buy) | |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 170.59 per share. | 22 Jun 2020 | 35,757 | 87,141 (0%) | 0% | 170.6 | 6,099,787 | Common Stock |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 169.56 per share. | 22 Jun 2020 | 8,086 | 122,898 (0%) | 0% | 169.6 | 1,371,062 | Common Stock |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 168.61 per share. | 22 Jun 2020 | 6,009 | 130,984 (0%) | 0% | 168.6 | 1,013,177 | Common Stock |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.71 per share. | 22 Jun 2020 | 1,858 | 35,009 (0%) | 0% | 13.7 | 25,473 | Common Stock |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 1,858 | 0 | - | - | Stock option (right to buy) | |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.71 per share. | 22 Jun 2020 | 1,280 | 33,151 (0%) | 0% | 13.7 | 17,549 | Common Stock |
| Sarepta Therapeutics Inc | David T. Howton | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 1,280 | 0 | - | - | Stock option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges